spacer
home > ebr > autumn 2017 > eu impact
PUBLICATIONS
European Biopharmaceutical Review

EU Impact

25 May 2018 is an important date for pharmaceutical companies, CROs, software vendors and others supporting drug development, as this is when the new EU General Data Protection Regulation (GDPR) – what the EU calls “the most important change in data privacy regulation in 20 years” – comes into effect (1).

The new rules replace the 1995 Data Protection Directive 95/46/EC and are meant to harmonise data privacy laws across Europe, as well as “to protect and empower all EU citizens’ data privacy”. The GDPR will have a significant impact on how patient data are handled as it changes the way organisations approach information security.

When GDPR comes into effect, national governments will not be required to pass enabling legislation. The regulation will be applicable immediately, and serious violations may result in fines of €20 million or 4% of the organisation's worldwide revenues.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Jon Weisberg, Industry Advisor for EBR, heads public relations and communications for SAFE-BioPharma Association. He provides comprehensive editorial and consulting services to life sciences organisations.
spacer
Jon Weisberg
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Charles River Laboratories Makes Investments in High-Throughput Screening Infrastructure

WILMINGTON, Mass.--(BUSINESS WIRE)--Feb. 1, 2018-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced a new agreement which grants Charles River commercial access to AstraZeneca’s (NYSE: AZN) high-throughput screening (HTS) and compound management infrastructure. Through the agreement, Charles River will perform HTS programs for its clients utilizing AstraZeneca’s state-of-the-art HTS facility.
More info >>

White Papers

Working Towards a Standardised Identification Solution

PCI Pharma Services

The security of the pharmaceutical supply chain is an issue of growing concern, with recent reports addressing its vulnerability to counterfeiting. The complexity of the European supply chain is one of the key factors of this counterfeiting pandemic, with millions of medicine packs being moved around the EU, annually. Aside from this, fragmentation has resulted in decreased transparency in the supply chain and increased difficulties to track and trace medicines, leading to significant threat from counterfeiting. As a key source of income for the European economy, it is essential that the supply chain remains safe and free of counterfeits. A significant stumbling block within the industry remains to be the lack of a unified, single‐source pan‐European or indeed global database where scanned bar codes on drug packaging can be verified at point of dispense. At some point in the future the pharmaceutical industry, regulatory bodies, clinicians and retailers will need to join forces to overcome this.
More info >>

 
Industry Events

INTERPHEX 2018

17-18 April 2018, Javits Center, New York, USA

At INTERPHEX, find all of the State-of-the-Art Solutions you need to Cost Effectively Develop and Manufacture Product. INTERPHEX is a premier pharmaceutical, biotechnology, and medical device development and manufacturing event and sponsored by Parenteral Drug Association (PDA).
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement